BIOCRYST PHARMACEUTICALS, INC. Operating Lease, Expense
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Operating Lease, Expense of $781.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-06-30 was $781.00K, a 48.48% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-03-31 was $706.00K, a 29.78% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-12-31 was $411.00K, a 26.61% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-09-30 was $526.00K, a 7.56% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, expense for fiscal 2025 was $2.01M, a 12.78% decline from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, expense for fiscal 2024 was $2.30M, a 14.02% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, expense for fiscal 2023 was $2.02M, a 27.88% increase from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, expense for fiscal 2022 was $1.58M, a 4.94% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month | Operating Lease, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $781.00K 10-Q · filed 2026-08-05 | $1.49M 10-Q · filed 2026-08-05 | $1.90M derived: sum of 3 quarters · filed 2026-08-05 | $2.42M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $706.00K 10-Q · filed 2026-05-06 | $1.12M derived: sum of 2 quarters · filed 2026-05-06 | $1.64M derived: sum of 3 quarters · filed 2026-05-06 | $2.17M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $411.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $937.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.46M derived: sum of 3 quarters · filed 2026-08-05 | $2.01M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $526.00K 10-Q · filed 2025-11-04 | $1.05M derived: sum of 2 quarters · filed 2026-08-05 | $1.60M 10-Q · filed 2025-11-04 | $2.16M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $526.00K 10-Q · filed 2026-08-05 | $1.07M 10-Q · filed 2026-08-05 | $1.63M derived: sum of 3 quarters · filed 2026-08-05 | $2.20M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $544.00K 10-Q · filed 2026-05-06 | $1.10M derived: sum of 2 quarters · filed 2026-05-06 | $1.67M derived: sum of 3 quarters · filed 2026-05-06 | $2.25M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $560.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.13M derived: sum of 2 quarters · filed 2026-02-26 | $1.71M derived: sum of 3 quarters · filed 2026-02-26 | $2.30M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $569.00K 10-Q · filed 2025-11-04 | $1.15M derived: sum of 2 quarters · filed 2025-11-04 | $1.74M 10-Q · filed 2025-11-04 | $2.20M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $582.00K 10-Q · filed 2025-08-05 | $1.17M 10-Q · filed 2025-08-05 | $1.63M derived: sum of 3 quarters · filed 2026-02-26 | $2.30M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $590.00K 10-Q · filed 2025-05-06 | $1.05M derived: sum of 2 quarters · filed 2026-02-26 | $1.72M derived: sum of 3 quarters · filed 2026-02-26 | $2.17M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $459.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.13M derived: sum of 2 quarters · filed 2026-02-26 | $1.58M derived: sum of 3 quarters · filed 2026-02-26 | $2.02M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $666.00K 10-Q · filed 2024-11-05 | $1.13M derived: sum of 2 quarters · filed 2024-11-05 | $1.56M 10-Q · filed 2024-11-05 | ||
| 2023-06-30 | $460.00K 10-Q · filed 2024-08-06 | $893.00K 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | $433.00K 10-Q · filed 2024-05-07 | ||||
| 2022-12-31 | $1.58M 10-K · filed 2025-02-25 | $2.53M 10-K · filed 2023-02-27 | |||
| 2022-03-31 | $594.00K 10-Q · filed 2022-05-09 | $948.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.34M derived: sum of 3 quarters · filed 2024-02-27 | $1.80M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $354.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $747.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.21M derived: sum of 3 quarters · filed 2024-02-27 | $1.66M 10-K · filed 2024-02-27 | $1.79M 10-K · filed 2022-02-28 |
| 2021-09-30 | $393.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $854.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.31M 10-Q · filed 2021-11-04 | $1.74M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2021-06-30 | $461.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $913.00K 10-Q · filed 2021-08-09 | $1.35M derived: sum of 3 quarters · filed 2022-05-09 | $1.73M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2021-03-31 | $452.00K 10-Q · filed 2022-05-09 | $885.00K derived: sum of 2 quarters · filed 2022-05-09 | $1.27M derived: sum of 3 quarters · filed 2022-05-09 | $1.76M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $433.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $819.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.31M derived: sum of 3 quarters · filed 2022-02-28 | $1.75M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $386.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $873.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.32M 10-Q · filed 2021-11-04 | $1.72M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | $487.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $935.00K 10-Q · filed 2021-08-09 | $1.33M derived: sum of 3 quarters · filed 2021-08-09 | $1.69M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $448.00K 10-Q · filed 2021-05-07 | $848.00K derived: sum of 2 quarters · filed 2021-05-07 | $1.21M derived: sum of 3 quarters · filed 2021-05-07 | $1.60M derived: sum of 4 quarters · filed 2021-05-07 | |
| 2019-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $758.00K derived: sum of 2 quarters · filed 2021-03-01 | $1.16M derived: sum of 3 quarters · filed 2021-03-01 | $1.46M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $358.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $755.00K derived: sum of 2 quarters · filed 2020-11-06 | $1.06M 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $397.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $706.00K 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | $309.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |